应用冠状动脉影像进行一级预防的试验设计:美国国家心肺血液研究所研讨会
美国国家心肺血液研究所于2019年8月26日至27日在马里兰州贝塞斯达召开多学科工作组会议,评估冠状动脉钙化(CAC)检测及其他冠状动脉影像检查用于指导心血管疾病一级预防决策的证据。工作组认为,支持现有指南推荐在中年成人中使用CAC的额外证据很可能来自正在进行的该年龄段试验,新试验可能不及时或不具成本效益;现有试验未涉及年轻或老年成人中CAC检测的作用,也未涉及人工智能辅助的机会性筛查策略的潜在获益。
要点
- CAC被视为增强一级预防风险评的有用检测,相关临床试验正在考虑中。
- 工作组认为支持中年成人CAC指南推荐的额外证据很可能来自正在进行的试验。
- 现有试验未覆盖年轻和老年成人,也未覆盖人工智能辅助的机会性筛查策略。
核心结论
- 工作组认为,支持现有指南推荐在中年成人中使用CAC的额外证据很可能来自正在进行的该年龄段试验,新试验可能不及时或不具成本效益。
研究设计与样本
- 美国国家心肺血液研究所于2019年8月26日至27日在马里兰州贝塞斯达召开多学科工作组会议,审查现有证据并考虑进一步研究CAC检测或其他冠状动脉影像检查以指导心血管疾病一级预防治疗的适当性。
临床应用与阅片要点
- 现有试验不会涉及CAC检测在年轻成人或老年成人中的作用,这些人群在现有指南中亦未涉及。
- 现有试验不会涉及人工智能应用所实现的机会性筛查策略的潜在获益。
- 工作组强烈考虑了几种创新试验设计来检验CAC在整个生命周期中的价值,这些设计代表了额外研究的重要机会,尤其是利用现有试验或其他真实世界数据流(包括临床计算机断层扫描)的设计。
- 心血管疾病发病率和死亡率的性别和种族/民族差异,以及未来CAC试验(尤其是美国开展的试验)纳入多样化参与者,将增强这些研究的潜在影响。
局限性
- 现有指南未涉及年轻成人和老年成人中CAC检测的作用。
- 现有试验未涉及人工智能辅助的机会性筛查策略的潜在获益。
- 新试验可能不及时或不具成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Coronary artery calcium (CAC) is considered a useful test for enhancing risk assessment in the primary prevention setting. Clinical trials are under consideration. The National Heart, Lung, and Blood Institute convened a multidisciplinary working group on August 26 to 27, 2019, in Bethesda, Maryland, to review available evidence and consider the appropriateness of conducting further research on coronary artery calcium (CAC) testing, or other coronary imaging studies, as a way of informing decisions for primary preventive treatments for cardiovascular disease. The working group concluded that additional evidence to support current guideline recommendations for use of CAC in middle-age adults is very likely to come from currently ongoing trials in that age group, and a new trial is not likely to be timely or cost effective. The current trials will not, however, address the role of CAC testing in younger adults or older adults, who are also not addressed in existing guidelines, nor will existing trials address the potential benefit of an opportunistic screening strategy made feasible by the application of artificial intelligence. Innovative trial designs for testing the value of CAC across the lifespan were strongly considered and represent important opportunities for additional research, particularly those that leverage existing trials or other real-world data streams including clinical computed tomography scans. Sex and racial/ethnic disparities in cardiovascular disease morbidity and mortality, and inclusion of diverse participants in future CAC trials, particularly those based in the United States, would enhance the potential impact of these studies.
引用
- Greenland P, Michos ED, Redmond N, et al. Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop. JACC Cardiovasc Imaging. 2020. PMID: 32950442. doi:10.1016/j.jcmg.2020.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。